Keywords

Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Schizophrenia

Research group(s)

• Clinical Neuroimaging
• Psychosis Imaging Group (Head: M. Willeit)

Selected publications

1. Bartova, L. et al., 2019. Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. The World Journal of Biological Psychiatry, 20(6), pp.427–448. Available at: http://dx.doi.org/10.1080/15622975.2019.1635270.
2. Bartova, L. et al., 2018. Rapid antidepressant effect of S-ketamine in schizophrenia. European Neuropsychopharmacology, 28(8), pp.980–982. Available at: http://dx.doi.org/10.1016/j.euroneuro.2018.05.007.
3. Bartova, L. et al., 2017. Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression. The Journal of ECT, 33(3), pp.e31–e32. Available at: http://dx.doi.org/10.1097/YCT.0000000000000421.
4. Bartova, L. et al., 2015. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases. European Neuropsychopharmacology, 25(11), pp.2183–2184. Available at: http://dx.doi.org/10.1016/j.euroneuro.2015.07.021.
5. Bartova, L. et al., 2015. Reduced default mode network suppression during a working memory task in remitted major depression. Journal of Psychiatric Research, 64, pp.9–18. Available at: http://dx.doi.org/10.1016/j.jpsychires.2015.02.025.